Hester Biosciences Limited (NSE:HESTERBIO)
2,083.00
-34.70 (-1.64%)
Sep 12, 2025, 3:30 PM IST
Hester Biosciences Revenue
Hester Biosciences had revenue of 864.21M INR in the quarter ending June 30, 2025, with 3.51% growth. This brings the company's revenue in the last twelve months to 3.15B, up 3.18% year-over-year. In the fiscal year ending March 31, 2025, Hester Biosciences had annual revenue of 3.12B with 0.41% growth.
Revenue (ttm)
3.15B
Revenue Growth
+3.18%
P/S Ratio
5.60
Revenue / Employee
5.61M
Employees
562
Market Cap
17.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 3.12B | 12.80M | 0.41% |
Mar 31, 2024 | 3.11B | 329.89M | 11.86% |
Mar 31, 2023 | 2.78B | 315.58M | 12.79% |
Mar 31, 2022 | 2.47B | 289.51M | 13.30% |
Mar 31, 2021 | 2.18B | 299.33M | 15.94% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Hester Biosciences News
- 5 weeks ago - Q1 2026 Hester Biosciences Ltd Earnings Call Transcript - GuruFocus
- 6 weeks ago - Hester Biosciences shares rally 15% as Q1 profit soars 131% YoY to Rs 17.3 crore, revenue rises 2% - Business Upturn
- 7 months ago - India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc. - Benzinga